Shares of BTG plc (LON:BTG – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 0 and traded as high as GBX 120. BTG shares last traded at GBX 118.50, with a volume of 148,552 shares traded.
Analyst Upgrades and Downgrades
Separately, Shore Capital Group reissued a “house stock” rating on shares of BTG in a report on Tuesday, February 3rd.
Read Our Latest Stock Analysis on BTG
BTG Stock Performance
About BTG
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease.
Read More
- Five stocks we like better than BTG
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.
